BHVN Deadline: BHVN Investors with Losses in Excess of $100K Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class period for the Biohaven securities is from March 24, 2023, to May 14, 2025, inclusive [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 12, 2025 [2] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] Group 3: Allegations Against Biohaven - The lawsuit alleges that Biohaven made false and misleading statements regarding the regulatory prospects of its drug, troriluzole, and its efficacy for treating bipolar disorder [4] - It is claimed that the overstated prospects were likely to negatively impact Biohaven's business and financial condition once revealed [4] - Investors are said to have suffered damages when the true details about the company's statements became public [4]